Company news
SciBase Holding AB news in 2026
SciBase Holding AB's news releases, calls and decks from 2026, newest first.
SciBase rights issue registered, conversion of BTA into shares
October 9, 2026
SciBase: Recalculation of warrants of series TO 2 following rights issue
October 7, 2026
SciBase resolves on a set-off issue of shares to the guarantor in connection with the completed rights issue
October 7, 2026
SciBase announces outcome of rights issue of shares
October 1, 2026
SciBase announces confirmed guarantee commitment in connection with ongoing rights issue
September 25, 2026
Updated first day of trading in subscription rights and paid-up subscribed shares
September 15, 2026
SciBase publishes information document regarding the rights issue
September 14, 2026
SciBase receives additional order from Castle Biosciences, advancing the collaboration
September 8, 2026
SciBase resolves on a rights issue of shares of approximately SEK 58 million
September 3, 2026
SciBase announces changes in senior management
July 28, 2026
SciBase Submits FDA 510(k) to Expand Nevisense into the Largest Skin Cancer Market
July 1, 2026
First Patient Enrolled in New Study Assessing early prediction of flares in Atopic Dermatitis by Castle Biosciences in Collaboration with SciBase
June 10, 2026
Study that highlights Nevisense potential for prediction of AD published in leading journal
June 9, 2026
SciBase announces that the board of directors has resolved on the record date for the reverse share split
May 28, 2026
Nevisense detects skin barrier damage by chemicals used in household cleaning products in a new ex-vivo study
May 28, 2026
Bulletin from the annual general meeting in SciBase Holding AB (publ)
May 19, 2026
SciBase Announces New Research Highlighting Nevisense's Potential in Detecting Age-Related Skin Barrier Changes
May 18, 2026
SciBase publishes the Annual report for 2025
April 27, 2026
Notice to attend the annual general meeting in Scibase Holding AB (publ)
April 14, 2026
SciBase reaches milestone with over 400,000 tests sold with Nevisense
April 7, 2026
New Study Positions Nevisense's EIS as a valuable and sensitive tool for assessing skin barrier impairment
March 10, 2026
New Publication: US clinicians' real-world Nevisense experience improves melanoma detection
March 5, 2026
SciBase receives approval by FDA for extended labelling in the US
March 2, 2026
SciBase's Nevisense (EIS) Included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanoma
February 19, 2026
A new study demonstrates that Nevisense can predict atopic dermatitis in Newborns
February 17, 2026
SciBase: Recalculation of warrants of series TO 2 following rights issue and updated last day of trading in BTA from the rights issue
February 6, 2026
SciBase announces final outcome of the rights issue and the resolution on a set-off issue within the framework of the offer to repurchase outstanding warrants of series TO 2
January 27, 2026
Change of date for publication of the year-end report for the financial year 2025
January 26, 2026
Increased commitment in SciBase rights issue
January 22, 2026
SciBase publishes information document regarding rights issue
January 9, 2026
SciBase announces outcome of the offer to repurchase outstanding warrants of series TO 2
January 9, 2026